Radiotherapy planning in a prostate cancer phantom model with intraprostatic dominant lesions using stereotactic body radiotherapy with volumetric modulated arcs and a simultaneous integrated boost.

DIL SBRT-SIB VMAT patient-specific quality assurance phantom model transit and non-transit dosimetry

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2023
Historique:
received: 18 01 2023
accepted: 10 04 2023
medline: 16 5 2023
pubmed: 16 5 2023
entrez: 15 5 2023
Statut: epublish

Résumé

In the treatment of prostate cancer with radiation therapy, the addition of a simultaneous integrated boost (SIB) to the dominant intraprostatic lesions (DIL) may improve local control. In this study, we aimed to determine the optimal radiation strategy in a phantom model of prostate cancer using volumetric modulated arc therapy for stereotactic body radiotherapy (SBRT-VMAT) with a SIB of 1-4 DILs. We designed and printed a three-dimensional anthropomorphic phantom pelvis to simulate individual patient structures, including the prostate gland. A total of 36.25 Gy (SBRT) was delivered to the whole prostate. The DILs were irradiated with four different doses (40, 45, 47.5, and 50 Gy) to assess the influence of different SIB doses on dose distribution. The doses were calculated, verified, and measured using both transit and non-transit dosimetry for patient-specific quality assurance using a phantom model. The dose coverage met protocol requirements for all targets. However, the dose was close to violating risk constraints to the rectum when four DILs were treated simultaneously or when the DILs were located in the posterior segments of the prostate. All verification plans passed the assumed tolerance criteria. Moderate dose escalation up to 45 Gy seems appropriate in cases with DILs located in posterior prostate segments or if there are three or more DILs located in other segments.

Identifiants

pubmed: 37188175
doi: 10.3389/fonc.2023.1147593
pmc: PMC10175813
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1147593

Informations de copyright

Copyright © 2023 Skrobala, Kruszyna-Mochalska, Graczyk, Ryczkowski, Fundowicz, Milecki and Malicki.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Urol. 2007 Oct;178(4 Pt 1):1249-52
pubmed: 17698131
Front Oncol. 2021 Sep 15;11:744130
pubmed: 34604088
Phys Imaging Radiat Oncol. 2020 Nov 09;16:113-129
pubmed: 33458354
J Appl Clin Med Phys. 2019 Jun;20(6):79-90
pubmed: 31083776
J Urol. 2017 Feb;197(2):320-326
pubmed: 27484386
Tumori. 2022 Jun;108(3):263-269
pubmed: 33896239
Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):614-20
pubmed: 20932672
Acta Oncol. 2015;54(9):1543-50
pubmed: 26397055
Radiother Oncol. 2014 Dec;113(3):398-403
pubmed: 25441610
Radiother Oncol. 2013 Jun;107(3):274-81
pubmed: 23791306
Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):971-977
pubmed: 26054865
Acta Oncol. 2005;44(3):265-76
pubmed: 16076699
Br J Radiol. 2002 Feb;75(890):151-61
pubmed: 11893639
Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):244-54
pubmed: 11516874
Acta Oncol. 2011 Jan;50(1):25-34
pubmed: 21174609
Eur J Cancer. 2016 May;59:142-151
pubmed: 27035363
Adv Radiat Oncol. 2018 Sep 19;4(1):90-95
pubmed: 30706015
Phys Med. 2013 Nov;29(6):592-8
pubmed: 23103321
Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):509-17
pubmed: 24929162
Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):406-15
pubmed: 24685447
Med Phys. 2018 Apr;45(4):e53-e83
pubmed: 29443390
JAMA Oncol. 2015 Oct;1(7):897-906
pubmed: 26181727
Phys Med. 2021 Nov 22;92:8-14
pubmed: 34823110
J Clin Oncol. 2014 Nov 10;32(32):3680-1
pubmed: 25135989
Clin Oncol (R Coll Radiol). 2018 Jan;30(1):5-14
pubmed: 29033164
Front Oncol. 2022 Jul 07;12:889132
pubmed: 35875062
Trials. 2011 Dec 05;12:255
pubmed: 22141598
Pract Radiat Oncol. 2018 Nov - Dec;8(6):354-360
pubmed: 30322661
Cancer. 2007 Aug 15;110(4):906-10
pubmed: 17587207
Radiat Oncol. 2013 Oct 02;8:228
pubmed: 24088319

Auteurs

Agnieszka Skrobala (A)

Department of Electroradiology, Poznan University of Medical Science, Poznan, Poland.
Department of Medical Physics, Greater Poland Cancer Centre, Poznan, Poland.

Marta Kruszyna-Mochalska (M)

Department of Electroradiology, Poznan University of Medical Science, Poznan, Poland.
Department of Medical Physics, Greater Poland Cancer Centre, Poznan, Poland.

Kinga Graczyk (K)

Department of Medical Physics, Greater Poland Cancer Centre, Poznan, Poland.

Adam Ryczkowski (A)

Department of Medical Physics, Greater Poland Cancer Centre, Poznan, Poland.

Magdalena Fundowicz (M)

Department of Radiation Oncology I, Greater Poland Cancer Centre, Poznan, Poland.

Piotr Milecki (P)

Department of Electroradiology, Poznan University of Medical Science, Poznan, Poland.
Department of Radiation Oncology I, Greater Poland Cancer Centre, Poznan, Poland.

Julian Malicki (J)

Department of Electroradiology, Poznan University of Medical Science, Poznan, Poland.

Classifications MeSH